Supplemental marine omega-3 eicosapentaenoic acid (EPA) has an anti-atherosclerotic effect. Clinical research on EPA supplied by the regular diet and atherosclerosis is scarce. In the framework of the PREvención con DIeta MEDiterránea (PREDIMED) trial, we conducted a cross-sectional study in 161 older individuals at high vascular risk grouped into different stages of carotid atherosclerosis severity, including those without ultrasound-detected atheroma plaque (n = 38), with plaques <2.0 mm thick (n = 65), and with plaques ≥2.0 mm (n = 79). The latter were asked to undergo contrast-enhanced 3T magnetic resonance imaging (MRI) and were subsequently grouped into absence (n = 31) or presence (n = 27) of MRI-detectable plaque lipid, a main featu...
Background: Non-alcoholic fatty liver disease (NAFLD) is a spectrum of conditions ranging from simpl...
Many chronic inflammatory processes are linked with the continuous release of inflammatory mediators...
ObjectiveDespite available medical therapies, patients with peripheral arterial disease (PAD) remain...
Supplemental marine omega-3 eicosapentaenoic acid (EPA) has an anti-atherosclerotic effect. Clinical...
Supplemental marine omega-3 eicosapentaenoic acid (EPA) has an anti-atherosclerotic effect. Clinical...
ObjectiveTo examine n?3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques...
Introduction: Increased intake of the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoi...
AbstractResidual cardiovascular (CV) risk remains in dyslipidemic patients despite intensive statin ...
Abstract Background Despite the success of HMG-CoA reductase inhibitor (statin) therapy in reducing ...
Background and Purpose- We hypothesized that total marine n-3 polyunsaturated fatty acids (PUFA), in...
Background: N-3 polyunsaturated fatty acids (PUFAs) from oily fish protect against death from cardio...
Copyright © 2011 Jennifer S. Anderson et al. This is an open access article distributed under the Cr...
Background: Marine omega-3 eicosapentaenoic acid (EPA) is readily incorporated into cardiomyocyte m...
Instability of atherosclerotic plaques is due to macrophage inflammatory activity and can result in ...
Purpose of reviewThe omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA) and docosahexaenoic a...
Background: Non-alcoholic fatty liver disease (NAFLD) is a spectrum of conditions ranging from simpl...
Many chronic inflammatory processes are linked with the continuous release of inflammatory mediators...
ObjectiveDespite available medical therapies, patients with peripheral arterial disease (PAD) remain...
Supplemental marine omega-3 eicosapentaenoic acid (EPA) has an anti-atherosclerotic effect. Clinical...
Supplemental marine omega-3 eicosapentaenoic acid (EPA) has an anti-atherosclerotic effect. Clinical...
ObjectiveTo examine n?3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques...
Introduction: Increased intake of the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoi...
AbstractResidual cardiovascular (CV) risk remains in dyslipidemic patients despite intensive statin ...
Abstract Background Despite the success of HMG-CoA reductase inhibitor (statin) therapy in reducing ...
Background and Purpose- We hypothesized that total marine n-3 polyunsaturated fatty acids (PUFA), in...
Background: N-3 polyunsaturated fatty acids (PUFAs) from oily fish protect against death from cardio...
Copyright © 2011 Jennifer S. Anderson et al. This is an open access article distributed under the Cr...
Background: Marine omega-3 eicosapentaenoic acid (EPA) is readily incorporated into cardiomyocyte m...
Instability of atherosclerotic plaques is due to macrophage inflammatory activity and can result in ...
Purpose of reviewThe omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA) and docosahexaenoic a...
Background: Non-alcoholic fatty liver disease (NAFLD) is a spectrum of conditions ranging from simpl...
Many chronic inflammatory processes are linked with the continuous release of inflammatory mediators...
ObjectiveDespite available medical therapies, patients with peripheral arterial disease (PAD) remain...